Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | MMP3 | P08254 | 5/20 | 0.46 |
| ▸ | MMP8 | P22894 | 4/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | MMP1 | P03956 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258301 | 0.92 | CYP2D6 (0.53) | CYP2D6KCNH2 | |
| SCHEMBL1258303 | 0.92 | CYP2D6 (0.53) | CYP2D6KCNH2 | |
| SCHEMBL1258247 | 0.88 | PPARG (0.44) | CYP2D6KCNH2MMP3MMP8MMP9 | |
| SCHEMBL1258248 | 0.88 | PPARG (0.44) | CYP2D6KCNH2MMP3MMP8MMP9 | |
| SCHEMBL3934718 | 0.87 | CYP2D6 (0.61) | CYP2D6KCNH2 | |
| SCHEMBL3934714 | 0.87 | CYP2D6 (0.61) | CYP2D6KCNH2 | |
| SCHEMBL7795694 | 0.85 | MMP3 (0.51) | MMP3MMP8MMP9MMP1 | |
| SCHEMBL1257662 | 0.81 | CYP2D6 (0.54) | CYP2D6KCNH2 | |
| SCHEMBL1257663 | 0.81 | CYP2D6 (0.54) | CYP2D6KCNH2 | |
| SCHEMBL1258308 | 0.80 | CYP2D6 (0.53) | CYP2D6KCNH2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879911-B2 | 2-(4-Fluorophenoxy-N-hydroxyacetamide where the \"oxy\" can also be sulfonyl, sulfamyl or sulfinyl; enzyme inhibitors of the \"lethal factor\" enzyme released by bacillus anthraci that splits an essential peptide needed by mammals for signal transmission; antidotes; biological warfare | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-01 | — | — | US | disclosed |
| US-7879911-B2 | 2-(4-Fluorophenoxy-N-hydroxyacetamide where the \"oxy\" can also be sulfonyl, sulfamyl or sulfinyl; enzyme inhibitors of the \"lethal factor\" enzyme released by bacillus anthraci that splits an essential peptide needed by mammals for signal transmission; antidotes; biological warfare | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-01 | — | — | US | disclosed |
| WO-2009008905-A1 | HYDROXAMIC ACID DERIVATIVES OF PHENOXY-ACETIC ACIDS AND ANALOGS USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARMA, LLC. | 2009-01-15 | — | — | WO | disclosed |
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188565-A1 | Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning | ANTXR2, HAAO, PAOX | CYP2D6 1567/4885KCNH2 2817/4885MMP3 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.